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Abstract
Background Cancer cachexia is characterized by loss of
both adipose and skeletal muscle tissue and by an increased
production of proinflammatory cytokines. Ursodeoxycholic
acid (UDCA), a bile acid used for centuries in the treatment
of liver disease, is known to confer anti-inflammatory and
anti-apoptotic effects as well as beneficial effects on
mitochondrial integrity and cell signaling. We hypothesized
that UDCA ameliorates the wasting process in the Yoshida
hepatoma tumor model. In addition, we sought to establish
if UDCA exerts beneficial effects on survival in this model.
Methods and results Forty-seven male rats were inoculated
intraperitoneally with 10
8 Yoshida hepatoma AH-130 cells
and treated with placebo or one of two different doses of
UDCA, 25 or 100 mg/kg daily. Body weight, body
composition, and activity indicators were measured over
the course of study up to day 16. UDCA treatment had no
effect on tumor growth, loss of body weight, and loss of fat
mass. Compared with placebo, low-dose UDCA improved
tissue loss in the lung (p=0.022) and tended to reduce
tissue loss in brown adipocytes (p=0.06), gastrocnemius
muscle (p=0.06), extensor digitorum longus muscle (p=
0.09), and soleus muscle (p=0.07). Compared with
placebo, high-dose UDCA tended to reduce the loss of
lean body mass (p=0.06), lung tissue (p=0.1), white
a d i p o s et i s s u e( p=0.11), and gastrocnemius muscle (p=
0.11). The activity and food intake were not altered in
tumor-bearing rats by either dose of UDCA. Both doses
tended to decrease the mortality rate in tumor-bearing rats,
(hazard ratio (HR), 0.42; 95% confidence interval (CI),
0.17–1.04; p=0.061 for low-dose UDCA; HR, 0.44; 95%
CI, 0.18–1.05; p=0.065 for high-dose UDCA).
Conclusion UDCA treatment in the Yoshida hepatoma
model showed a trend towards attenuation of tissue loss
in animals with progressive weight loss in cancer cachexia.
Tumor growth and activity indicators were not altered. Both
doses of UDCA tended to reduce the mortality rates in
tumor-bearing animals. Larger studies with longer follow-
up are required to verify these findings.
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1 Introduction
Alterations in body composition are a frequent clinical
finding in patients with malignant cancer. Muscle loss
with ensuing decrease in strength may develop even
before weight loss becomes evident [1]. Cachexia as a
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metabolic syndrome associated with underlying illness
and characterized by” weight loss as a consequence of
muscle loss with or without loss of fat mass [2]. The
prevalence of cachexia among patients with malignant
cancer ranges between 20% and 80% during advanced
disease stages, dependent on the primary tumor site, co-
morbidites, and the presence or absence of metastases [3].
Furthermore, cachexia is associated with anorexia, sys-
temic inflammation, and a reduced quality of life as a
consequence of restricted mobility and a higher morbidity
[2, 4, 5]. Muscle wasting occurs by activation of
proteolytic systems, mainly the ubiquitin proteasome
pathway, and apoptosis [4].
Ursodeoxycholic acid (UDCA) is a tertiary bile acid that
has been used for centuries in the clinical treatment of
gallstones, primary biliary cirrhosis, and primary sclerosing
cholangitis [6–8]. It is known that UDCA suppresses
secondary bile acids (cholic acid)-induced colonic carcino-
genesis [9, 10]. UDCA exerts anti-inflammatory effects by
inhibiting the NF-κB pathway and therefore reducing the
expression of tumor necrosis factor alpha (TNF-α)[ 7, 11,
12]. In addition, UDCA has anti-apoptotic action mediated
by preventing damage of the mitochondrial membrane,
release of ROS and consequently inhibiting the induction of
transcription factors responsible for proliferation and
apoptosis [6, 12–15]. Here, we hypothesized that the effects
of UDCA may translate into beneficial effects in an




Fifty-seven 7 weeks old male Wistar Han rats weighing
approximately 200 g were used. Animals were housed in
groups of three, at a constant temperature of 22°C and
exposed to a 12-h light cycle. Animals had free access to
food and water. On day 1, 47 rats were inoculated
intraperitoneally with 10
8 exponentially growing Yoshida
hepatoma AH-130 cells [16]. Blood samples and organ
collection were scheduled for day 16 but had to be
performed earlier in 35 animals because ethical standards
(apathy, reduced body temperature, and disturbed blood
flow) ruled out killing. All organs were weighted after
killing the animals. In addition, we assessed body weight
and body composition before tumor implantation and on
the day of killing. Quality-of-life indicators (spontaneous
activity and food and water intake) were measured on
days 0 and 10/11. Tumor cells were counted on the last
study day.
2.2 Treatment with UDCA
Rats were randomized to control (n=10), placebo (n=28),
25 mg kg
−1 day
−1 UDCA (n=9), and 100 mg kg
−1 day
−1
UDCA (n=10). UDCA was purchased as Ursofalk suspen-
sion from Dr. Falk Pharma GmbH, Freiburg, Germany.
Treatment with UDCA or placebo started 1 day after tumor
inoculation and was then given daily by gavage until the
end of the study.
2.3 Body composition
Body composition (lean mass, muscle mass, water content,
and fluids) was analyzed using an EchoMRI-700 (Echo
Medical Systems, Houston, Texas, USA). The rat was put
in a tube so that it could not move during the measurement
which takes 90 s. The analysis of the body structures are
based on nuclear magnetic resonance which measures the
resonance of magnetic active nuclei in the tissue.
2.4 Quality-of-life indicators
Spontaneous activity and food intake are indicators for
quality of life [17]. Animals were housed individually with
100 g of food, and their movement was measured by an
infrared scanner over 24 h with the Supermex Locomotor
System (Muromachi Kikai Co., Ltd., Tokyo, Japan).
2.5 Statistics
Data were analyzed with GraphPad PRISM 5.0 (GraphPad
Software, Inc, La Jolla, CA, USA). Results are shown as
mean±SEM. Data were analyzed for normal distribution
using the Kolmogorov–Smirnov test. If there was a normal
distribution, the data were analyzed with analysis of
variance followed by Student’s t test while data without
normal distribution were analyzed by Kruskal–Wallis and
Mann–Whitney U test. Survival was tested by Cox
proportional hazard analysis and hazard ratio (HR) and
95% confidence interval (CI) are shown. A p value of
<0.05 was considered significant.
3 Results
We studied 57 animals; 35 of them had to be killed before
day 16 because they reached ethical endpoints (day 11, n=9;
day 12, n=10; day 13, n=8; day 14, n=5;andday15,n=3).
UDCA treatment did not have an effect on the growth of the
Yoshida hepatoma tumor. At the end of the study or earlier in
cases that animals had to be killed, total tumor cell numbers
were 2.04±0.26×10
9 cells in placebo-treated animals, 1.95±
0.49×10
9 cells in animals that received 25 mg kg
−1 day
−1 of
32 J Cachexia Sarcopenia Muscle (2012) 3:31–36UDCA and 2.08±0.46×10
9 cells in animals that received
100 mg kg
−1 day
−1 of UDCA (p>0.5 both doses UDCA vs.
placebo). There were no observations of other malignancies
during necropsy.
3.1 Body weight and body composition
Control animals gained body weight (+59.30±2.80 g), lean
body mass (+40.70±2.61 g), and fat mass (+9.83±1.41 g).
Average loss in body weight was highest in the placebo
group (−53.36±3.06 g), which means 35.4% and was
slightly but not statistically significantly reduced in both
groups with UDCA treatment (−47.22±10.02 g for
25 mg kg
−1 day
−1 UDCA, 28.6%; −36.6±13.79 g for
100 mg kg
−1 day
−1 UDCA, 21.6%; Fig. 1a). The loss of
lean mass was slightly reduced by giving high-dose UDCA
(−27.53±9.73 g, p=0.06 vs. placebo; Fig. 1b), and the loss
of fat mass was not statistically significantly altered by
treating tumor-bearing animals with UDCA (p>0.5 both
doses vs. placebo; Fig. 1c).
3.2 Organ weights
Tumor-bearing rats lost significantly weight in nearly all
analyzed organs compared with control animals. Treatment
with both doses of UDCA did not attenuate the weight loss
in the heart, liver, spleen, kidney, fat tissue, and tibialis
muscle (Table 1). Treatment of cachectic animals with
25 mg kg
−1 day
−1 UDCA improved the weight of the lung
significantly (p=0.022 vs. placebo; Fig. 1d), and there was
a trend towards an increase in the weight of brown adipose
tissue (BAT), gastrocnemius muscle (GC; Fig. 1e), extensor
digitorum longus muscle (EDL), and soleus muscle (p=
0.06 for BAT and GC, p=0.09 for EDL, and p=0.07 for
soleus muscle; low-dose UDCA vs. placebo; Table 1).
High-dose UDCA attenuated somewhat but not significant-
ly the weight loss of the lung, white adipose tissue (WAT)
and GC (p=0.1 for lung, p=0.11 for WAT and GC vs.
placebo; Table 1 and Fig. 1e).
3.3 Quality of life
Indicators for quality of life are spontaneous activity and
food intake. The activity was decreased in tumor-bearing
animals, and there were no effects with either dose of
UDCA (Fig. 1f). Food intake was reduced in the placebo
group and UDCA treatment of the tumor-bearing animals
did not increase food intake (Fig. 1g).
3.4 Survival
On day 16 following tumor inoculation, the survival rates in
the placebo, high-, and low-dose UDCA groups were 11%,
40%, and 44%, respectively (Fig. 2). Median survival in the
abc
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Fig. 1 Change of body weight (a), lean body mass (b), and fat mass
(c): control animals gained weight and placebo animals lost
significantly body weight, lean body mass, and fat mass (p<0.001
vs. control); 100 mg kg
−1 day
−1 UDCA reduced loss of body weight
and fat mass but not significantly. Furthermore, the high dose of
UDCA prevents slightly the loss of lean mass (p=0.06 vs. placebo).
Weight of lung (d) and GC (e): 25 mg kg
−1 day
−1 UDCA improved
significantly the weight of the lung (p=0.022 vs. placebo). The same
dose improved the weight of the GC, but not significantly (p=0.06 vs.
placebo). Quality-of-life indicators: both doses of UDCA did not have
an effect on spontaneous activity (f) and food intake (g)
J Cachexia Sarcopenia Muscle (2012) 3:31–36 33placebo group was 12 days, 13 days for low-dose UDCA,
and 13.5 days for high-dose UDCA. Treatment with 25 and
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−1 day
−1 UDCA showed a trend towards
reducing mortality of the tumor-bearing animals (HR,
0.42; 95% CI, 0.17–1.04; p=0.061 for low-dose UDCA;
HR, 0.44; 95% CI, 0.18–1.05; p=0.065 for high-dose
UDCA). Combining both UDCA-treated animal groups for
the survival analysis increased the statistical power and
significantly decreased mortality of tumor-bearing animals
(HR, 0.40; 95% CI, 0.19–0.84; p=0.016 for UDCA
combined vs. placebo).
4 Discussion
In our study, UDCA treatment of tumor-bearing animals
had no effect on the growth of the tumor, loss of body
weight, and loss of fat mass. Low-dose UDCA attenuated
significantly the weight loss of the lung and slightly the
weight loss of BAT and skeletal muscles compared with
placebo. High-dose UDCA increased the lean body mass,
the weight of the lung, WAT, and gastrocnemius muscle
(GC). Both doses of UDCA had no effect on spontaneous
activity and food intake and tended to decrease mortality
rates in tumor-bearing animals.
It has been described that UDCA treatment can prevent
chemically induced colonic tumorigenesis in experimental
animal models and human colorectal cancer by inhibiting
proliferation of tumor cells [9, 10, 12, 18, 19]. In the
present study utilizing the Yoshida hepatoma animal model,
we could not confirm this, because the treatment with
UDCA had no effect on tumor growth. The reason therefore
that UDCA was not so beneficial in our tumor model could
be the type of the tumor (chemically induced tumor vs.
injected tumor cells) and the duration of the treatment.
Kohno et al. showed a prevention of colon carcinogenesis
in mice by giving UDCA (long-term) for 17 weeks after
chemical tumor induction [11]. Furthermore, Narisawa et
al. treated rats with colon cancer with UDCA for 27 weeks
and showed a suppression of cancer progression [9]. In our
case, long-term studies of rats inoculated with Yoshida
hepatoma cells are not feasible because the tumor cells are
too aggressive and hence UDCA treatment of 15 days may
be too short to shown any beneficial effect. Moreover, we
did not see an anti-cancer effect because it could be that we
did not assess the anticarcinogenic concentration of UDCA
in this tumor model and hence, more dose–response studies
are needed.
The body weight and the fat mass were unaltered in
UDCA-treated tumor-bearing rats compared with placebo.
Only high-dose UDCA affected the lean body mass;
25 mg kg
−1 day
−1 UDCA significantly increased the weight
of the lung and showed a trend towards increasing the
Table 1 Organ and tissue weights at day 16 (end of study) or day of death
Organ weight (mg) Control (n=10) Placebo (n=28) 25 mg kg
−1 day
−1 UDCA (n=9) 100 mg kg
−1 day
−1 UDCA (n=10)
Heart 781±16.5 520±17.2* 509±21* 529±33*
Lung 1,273±69 864±27* 992±71**
, *** 916±43*
, ****
Liver 10,600±393 6,325±265* 6,798±345* 6,265±684*
Spleen 641±30 189±30* 206±34* 222±57*
Kidney left 1,126±31 708±19.3* 690±32* 717±45*
Kidney right 1,162±39 735±22* 724±33* 729±42*
WAT 1,309±151 87±24* 301±155* 438±241***
, ****
BAT 220±12.1 83±4.77* 103±8.6*
, **** 96±14.0*
M. gastrocnemius 1,255±42 725±16.0* 828±81*
, **** 814±81*
, ****
M. tibialis 457±12.4 268±7.10* 296±23* 300±29*
M. EDL 107±3.66 64±1.51* 71±5.4*
, **** 68±6.3*
M. soleus 98±2.97 71±1.60* 79±5.2***
, **** 69±6.4*
*p<0.001 vs. control; **p<0.05 vs. placebo; ***p<0.01 vs. control; ****p<0.12 vs. placebo
Fig. 2 Kaplan–Meier survival curves, both doses UDCA slightly
reduce mortality compared with placebo
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placebo) while high-dose UDCA improved the weight of
the lung, WAT, and GC (p<0.12 vs. placebo). This effect
m a yb em e d i a t e db yU D C Ar e p o r t e dt ob ea n t i -
inflammatory and anti-apoptotic. In vitro and in vivo cancer
studies showed that UDCA treatment inhibits the NF-κB
pathway leading to the expression of the proinflammatory
cytokine TNF-α from which is known that it is associated
with wasting in cancer cachexia [7, 11, 12, 20]. A possible
mechanism explaining the anti-inflammatory and anti-
apoptotic effect could be that UDCA blocks the cancer
induced generation of reactive oxygen species and subse-
quently inhibiting the transcription factors AP-1, and NF-κB
important for carcinogenesis through the PKC signaling
pathway, established from other studies [7, 12, 21–24].
It was seen that high dose of UDCA did not exert
improved effects on body wasting than low-dose UDCA, so
there was no dose-dependent correlation. This may be
mediated by the fact that UDCA has side-effects like
diarrhea, and therefore UDCA is less absorbed.
The locomotor activity and food intake were unchanged
at day 10 after tumor inoculation compared with placebo
showing no effect of UDCA on improving quality of life.
The mortality of tumor-bearing animals treated with both
doses UDCA was reduced compared with placebo but did
reach significance when analyzing the combined UDCA
doses with placebo because of an increased statistical
power.
The results indicate that a low (25 mg kg
−1 day
−1) and
high (100 mg kg
−1 day
−1) dosage of UDCA had no effect
on tumor growth but slightly on body wasting and survival
in an experimental Yoshida hepatoma animal model. This
could be due to the kind of tumor, the fast tumor
progression, the unknown efficient UDCA concentration
and because of the short treatment time of UDCA. More
studies are needed to show an anti-cancer effect and a more
ameliorated cachexia to identify effects of higher doses or
longer treated periods.
4.1 Study limitations
The primary endpoint of this study was to investigate if
UDCA treatment could reduce body wasting in an
experimental cancer cachexia model. Due to the small
overall effects of UDCA treatment on body weight, we
did not analyze signaling mechanisms including TNF-α
measurement. The study was not powered for a survival
endpoint, but a combination of both treated groups
resulted in improved outcome. This suggests that a
study powered for survival should be performed.
However, since the effects on body weight and body
composition were minimal, it may not be relevant to
patient’s health.
A second limitation of the study is that we have used the
fast-growing and aggressive tumor AH-130 as a model for
cachexia in rats, which may be the reason that UDCA had
limited effects. However, further experiments could include
UDCA treatment in a less aggressive and therefore long-
term cancer cachexia animal model followed by measure-
ment of proinflammatory cytokines.
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